465 related articles for article (PubMed ID: 24053274)
1. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.
Brüggemann RJ; Antonius T; Heijst Av; Hoogerbrugge PM; Burger DM; Warris A
Ther Drug Monit; 2008 Dec; 30(6):643-6. PubMed ID: 19057370
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of voriconazole in children.
Chen J; Chan C; Colantonio D; Seto W
Ther Drug Monit; 2012 Feb; 34(1):77-84. PubMed ID: 22210097
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
5. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.
Bartelink IH; Wolfs T; Jonker M; de Waal M; Egberts TC; Ververs TT; Boelens JJ; Bierings M
Antimicrob Agents Chemother; 2013 Jan; 57(1):235-40. PubMed ID: 23114771
[TBL] [Abstract][Full Text] [Related]
6. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of voriconazole and posaconazole.
Hussaini T; Rüping MJ; Farowski F; Vehreschild JJ; Cornely OA
Pharmacotherapy; 2011 Feb; 31(2):214-25. PubMed ID: 21275497
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole in clinical practice.
Mikulska M; Novelli A; Aversa F; Cesaro S; de Rosa FG; Girmenia C; Micozzi A; Sanguinetti M; Viscoli C
J Chemother; 2012 Dec; 24(6):311-27. PubMed ID: 23174096
[TBL] [Abstract][Full Text] [Related]
9. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.
Boyd NK; Zoellner CL; Swancutt MA; Bhavan KP
Antimicrob Agents Chemother; 2012 Nov; 56(11):6001-2. PubMed ID: 22890768
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology and clinical use of voriconazole.
Thompson GR; Lewis JS
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):83-94. PubMed ID: 19947892
[TBL] [Abstract][Full Text] [Related]
11. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.
Aperis G; Mylonakis E
Expert Opin Investig Drugs; 2006 Jun; 15(6):579-602. PubMed ID: 16732713
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.
Maschmeyer G; Haas A
Future Microbiol; 2006 Dec; 1(4):365-85. PubMed ID: 17661629
[TBL] [Abstract][Full Text] [Related]
13. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole.
Med Lett Drugs Ther; 2002 Jul; 44(1135):63-5. PubMed ID: 12138377
[No Abstract] [Full Text] [Related]
15. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
van der Linden JW; Camps SM; Kampinga GA; Arends JP; Debets-Ossenkopp YJ; Haas PJ; Rijnders BJ; Kuijper EJ; van Tiel FH; Varga J; Karawajczyk A; Zoll J; Melchers WJ; Verweij PE
Clin Infect Dis; 2013 Aug; 57(4):513-20. PubMed ID: 23667263
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.
Clifton IJ; Whitaker P; Metcalfe R; Phillip M; Shaw N; Conway SP; Peckham DG
J Antimicrob Chemother; 2011 Oct; 66(10):2438-40. PubMed ID: 21791443
[No Abstract] [Full Text] [Related]
17. [Pharmacology of the antifungals used in the treatment of aspergillosis].
Azanza JR; Sádaba B; Gómez-Guíu A
Rev Iberoam Micol; 2014; 31(4):255-61. PubMed ID: 25442382
[TBL] [Abstract][Full Text] [Related]
18. Isavuconazole: Case Report and Pharmacokinetic Considerations.
Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.
George D; Miniter P; Andriole VT
Antimicrob Agents Chemother; 1996 Jan; 40(1):86-91. PubMed ID: 8787885
[TBL] [Abstract][Full Text] [Related]
20. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
